Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wyoming Tech Reporter.
Press releases published on August 11, 2025
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
GlobeNewswire
·
August 11, 2025
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results …
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 11, 2025
Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory …
Life360 Names COO Lauren Antonoff as Chief Executive Officer
GlobeNewswire
·
August 11, 2025
Co-Founder Chris Hulls will serve as Executive Chairman of the Board Planned leadership succession signals continued investment in product innovation and growth SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Life360 (Nasdaq: LIF), the category-defining …
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 11, 2025
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C- …
Synchronoss Technologies Reports Second Quarter 2025 Results
GlobeNewswire
·
August 11, 2025
Second Quarter Revenue of $42.5 Million, Including 92.6% Recurring Revenue Received CARES Act Tax Refund in Full, Amounting to $33.9 Million Reaffirms All Full Year Guidance Metrics BRIDGEWATER, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Synchronoss …
Assertio Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, …
BioVie Inc. Announces Closing of $12 Million Public Offering
GlobeNewswire
·
August 11, 2025
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 11, 2025
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 …
TELA Bio Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 11, 2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …
Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results
GlobeNewswire
·
August 11, 2025
Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $ …
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to Canada and the EU Company to host …
Rapid7 to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 11, 2025
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in threat detection and exposure management, today announced that the company will be attending the following conferences: The Canaccord Genuity 45th Annual Growth Conference in …
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 …
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
GlobeNewswire
·
August 11, 2025
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to …
Harrow Announces Second-Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 …
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 11, 2025
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
GlobeNewswire
·
August 11, 2025
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …